Leukemia :: First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
The first “antisense” drug to be tested in chronic lymphocytic leukemia (CLL) shows benefit in a phase III clinical trial for a specific subset of patients – those who are still sensitive to a chemotherapy drug often used to treat this cancer.